29131306|t|Comparative Effectiveness and Safety of Cognitive Enhancers for Treating Alzheimer's Disease: Systematic Review and Network Metaanalysis.
29131306|a|BACKGROUND/OBJECTIVES: To examine the comparative effectiveness and safety of cognitive enhancers for Alzheimer's disease (AD). DESIGN: Systematic review and Bayesian network metaanalysis (NMA). SETTING: MEDLINE, EMBASE, Cochrane Library, CINAHL, Ageline (inception-March 2016). PARTICIPANTS: Individuals with AD in randomized controlled trials (RCTs), quasi-RCTs, and nonrandomized studies. INTERVENTION: Any combination of donepezil, rivastigmine, galantamine, or memantine. MEASUREMENTS: Two reviewers independently screened titles, abstracts, and full-texts; abstracted data; and appraised risk of bias. RESULTS: Twenty thousand three hundred forty-three citations were screened, and 142 studies were included (110 RCTs, 21 non-RCTs, 11 cohort studies). NMA found that donepezil (Mini-Mental State Examination: mean difference (MD) = 1.39, 95% credible interval (CrI) = 0.53-2.24), donepezil+memantine (2.59, 95% CrI = 0.12-4.98), and transdermal rivastigmine (2.02, 95% CrI = 0.02-4.08) improved cognition more than placebo. NMA found that donepezil (Alzheimer's Disease Assessment Scale-cognitive: MD = -3.29, 95% CrI = -4.57 to -1.99) and galantamine (MD = -2.13, 95% CrI = -3.91 to -0.27) improved cognition more than placebo. NMA found that donepezil+memantine (MD = -5.23, 95% CrI = -8.72 to -1.56) improved behavior more than placebo. NMA found that donepezil (MD = -0.32, 95% CrI = -0.46 to -0.19), donepezil+memantine (MD = -0.57, 95% CrI = -0.95 to -0.21), oral rivastigmine (MD = -0.38, 95% CrI = -0.56 to -0.17), and galantamine (MD = -3.79, 95% CrI = -6.98 to -0.59) improved global status more than placebo. NMA found that galantamine decreased the odds of mortality (odds ratio = 0.56, 95% CrI = 0.36-0.87). No agent increased risk of serious adverse events, falls, or bradycardia. Some increased risk of headache (oral rivastigmine), diarrhea (oral rivastigmine, donepezil), nausea (oral rivastigmine, donepezil, galantamine), and vomiting (oral rivastigmine, donepezil, galantamine). CONCLUSION: An exhaustive review of the literature involving 142 studies demonstrated that cognitive enhancers in general have minimal effects on cognition according to minimal clinically important difference and global ratings. The drugs appear safe, but this must be interpreted cautiously because trial participants may have less comorbidity and fewer adverse effects than those treated with these drugs in clinical practice.
29131306	73	92	Alzheimer's Disease	Disease	MESH:D000544
29131306	240	259	Alzheimer's disease	Disease	MESH:D000544
29131306	261	263	AD	Disease	MESH:D000544
29131306	448	450	AD	Disease	MESH:D000544
29131306	563	572	donepezil	Chemical	MESH:D000077265
29131306	574	586	rivastigmine	Chemical	MESH:D000068836
29131306	588	599	galantamine	Chemical	MESH:D005702
29131306	604	613	memantine	Chemical	MESH:D008559
29131306	911	920	donepezil	Chemical	MESH:D000077265
29131306	1024	1033	donepezil	Chemical	MESH:D000077265
29131306	1034	1043	memantine	Chemical	MESH:D008559
29131306	1089	1101	rivastigmine	Chemical	MESH:D000068836
29131306	1183	1192	donepezil	Chemical	MESH:D000077265
29131306	1194	1213	Alzheimer's Disease	Disease	MESH:D000544
29131306	1284	1295	galantamine	Chemical	MESH:D005702
29131306	1388	1397	donepezil	Chemical	MESH:D000077265
29131306	1398	1407	memantine	Chemical	MESH:D008559
29131306	1499	1508	donepezil	Chemical	MESH:D000077265
29131306	1549	1558	donepezil	Chemical	MESH:D000077265
29131306	1559	1568	memantine	Chemical	MESH:D008559
29131306	1614	1626	rivastigmine	Chemical	MESH:D000068836
29131306	1671	1682	galantamine	Chemical	MESH:D005702
29131306	1779	1790	galantamine	Chemical	MESH:D005702
29131306	1916	1921	falls	Disease	MESH:C537863
29131306	1926	1937	bradycardia	Disease	MESH:D001919
29131306	1962	1970	headache	Disease	MESH:D006261
29131306	1977	1989	rivastigmine	Chemical	MESH:D000068836
29131306	1992	2000	diarrhea	Disease	MESH:D003967
29131306	2007	2019	rivastigmine	Chemical	MESH:D000068836
29131306	2021	2030	donepezil	Chemical	MESH:D000077265
29131306	2033	2039	nausea	Disease	MESH:D009325
29131306	2046	2058	rivastigmine	Chemical	MESH:D000068836
29131306	2060	2069	donepezil	Chemical	MESH:D000077265
29131306	2071	2082	galantamine	Chemical	MESH:D005702
29131306	2089	2097	vomiting	Disease	MESH:D014839
29131306	2104	2116	rivastigmine	Chemical	MESH:D000068836
29131306	2118	2127	donepezil	Chemical	MESH:D000077265
29131306	2129	2140	galantamine	Chemical	MESH:D005702
29131306	Comparison	MESH:D000077265	MESH:D005702
29131306	Positive_Correlation	MESH:D005702	MESH:D006261
29131306	Positive_Correlation	MESH:D000077265	MESH:D006261
29131306	Cotreatment	MESH:D000068836	MESH:D000077265
29131306	Negative_Correlation	MESH:D005702	MESH:D000544
29131306	Comparison	MESH:D005702	MESH:D008559
29131306	Positive_Correlation	MESH:D000077265	MESH:D003967
29131306	Positive_Correlation	MESH:D000077265	MESH:D009325
29131306	Negative_Correlation	MESH:D008559	MESH:D000544
29131306	Negative_Correlation	MESH:D000077265	MESH:D000544
29131306	Cotreatment	MESH:D000077265	MESH:D008559
29131306	Positive_Correlation	MESH:D000068836	MESH:D006261
29131306	Negative_Correlation	MESH:D000068836	MESH:D000544

